Back
Real-World Efficacy and Safety of Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer
Mark Tyson II, MD, MPH, and Jacob Moyer, BS, discuss the real-world use of nadofaragene firadenovec in non–muscle-invasive bladder cancer.
Real-World Efficacy and Safety of Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer
Episodes
All
All
Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.
Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.
Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.
The intravesical therapy nadofaragene firadenovec yielded a 79% 3-month CR rate in patients with CIS with or without papillary disease in a real-world study.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5